ClinicalTrials.gg
Not yet recruitingNCT07493252Updated Nov 19, 2026

A Behavioral Application for Improving Smoking Cessation Among Smokers

An interventional study of Smartphone app-based Intervention (Actify! A app) and Smartphone app-based Intervention (Actify! B app) in Cigarette Smoking-Related Carcinoma, sponsored by Fred Hutchinson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,812
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.

Planned enrollment
14th of 340
1,812 · median 96
Started
2027
with 6 others
No phase
226 of 371
41 open now
Primary completion
2029-07
later than 62 of 74 live
Registered
357th of 371
by date
Lead sponsor
9 of 371
Fred Hutchinson Cancer Center

Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 14th largest by planned enrollment of the 340 interventional ones that give a count, is one of 7 that started in 2027, is one of 226 with no phase, reaches primary completion later than 62 of the 74 other live ones, and was the 357th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 371 studies in Cigarette Smoking with a site in United States, or all of them as a file.
02

Study summary

This clinical trial compares two smartphone applications, called Actify! (A \& B) for improving smoking cessation outcomes in individuals who smoke. Actify! A is an app grounded in behavioral activation therapy, an evidence-based treatment for depression that can also be used to modify health behaviors such as smoking. The Actify! B app provides evidence-based tobacco cessation strategies based on current clinical guidelines.

Read the detailed description

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use the Actify! A app, which helps users identify personal values and meaningful activities, prompts users to schedule and complete meaningful activities, visualizes progress towards meeting activity and smoking-related goals, and provides tailored messages, resources, daily tips, personalized feedback, inspirational messages, and user stories, for 8 weeks on study.

ARM II: Participants use the Actify! B app, which contains quit advice, tools for tracking smokefree days, progress and cravings, guidance on preparing to quit, managing cravings and withdrawal, recovering from slips, and a mood management feature, for 8 weeks on study.

After completion of study intervention, participants are followed up at 6 months.

03

Conditions studied

  • Cigarette Smoking-Related Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Currently smoke, averaging at least 5 cigarettes/day for the last 30 days
  • Interested in quitting smoking in the next 30 days
  • Experience downloading and using one or more apps on their smartphone
  • Either screens negative for depression (Patient Health Questionnaire - 9 item [PHQ-9] score 0-4; n = 906) or screens positive for mild to moderately severe current depressive symptoms (PHQ-9 score 5-19; n = 906)
  • Willing and able to complete all study activities and to receive compensation by mail
  • Comfortable reading and writing in English
  • Have a mobile data plan and/or access to WiFi to support the use of the assigned app
  • Reside in the United States (US)
  • Willing to provide information for an emergency contact in case of serious concerns about the participant's physical or mental health

Exclusion criteria

Exclusion Criteria:

  • Self-report of currently receiving behavioral treatment for depression (e.g., psychotherapy or counseling, web- or app-based interventions); current use of pharmacotherapy for depression or for other mental health conditions that are not otherwise excluded is allowable (e.g., benzodiazepines, anticonvulsants, opioid agonists, antipsychotics)
  • Severe depression (PHQ-9 ≥ 20)
  • Current suicidal ideation reported on the PHQ-9
  • History of a suicide attempt
  • Self-reported lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, antisocial personality disorder, or borderline personality disorder; or self-reported lifetime diagnosis of an alcohol or drug use disorder with use of the substance(s) in the past 30 days
  • Currently receiving other smoking cessation treatments, including pharmacotherapies (nicotine replacement therapy, bupropion, or varenicline) and behavioral interventions (e.g. quitline counseling, other digital health programs), but excluding electronic (e)-cigarettes/vaping
  • Previous use of the QuitGuide program
  • Employees/family of investigator or study center
  • Member of the same household as another participant
  • Woman who is pregnant or breastfeeding, or planning to become pregnant
  • Having a Google voice number as their primary phone number (due to association with fraudulent study entry attempts in our previous work)
  • Currently incarcerated
  • Participated in earlier studies to develop the Actify! app
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,812 participants (estimated)

Study arms

  • Experimental
    Arm I (Actify! A app)

    Participants use the Actify! app, which helps users identify personal values and meaningful activities, prompts users to schedule and complete meaningful activities, visualizes progress towards meeting activity and smoking-related goals, and provides tailored messages, resources, daily tips, personalized feedback, inspirational messages, and user stories, for 8 weeks on study.

    Behavioral: Smartphone app-based Intervention (Actify! A app) · Other: Health Promotion and Education · Other: Survey Administration

  • Active comparator
    Arm II (Actify! B app)

    Participants use an app, which contains quit advice, tools for tracking smokefree days, progress and cravings, guidance on preparing to quit, managing cravings and withdrawal, recovering from slips, and a mood management feature, for 8 weeks on study.

    Behavioral: Smartphone app-based Intervention (Actify! B app) · Other: Health Promotion and Education · Other: Survey Administration

Interventions

  • BehavioralSmartphone app-based Intervention (Actify! A app)

    Use Actify! A app

  • BehavioralSmartphone app-based Intervention (Actify! B app)

    Use Actify! B app

  • OtherHealth Promotion and Education

    Receive motivational messages and smoking cessation information via text messages

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Self-reported 30-day point prevalence abstinence (PPA) from cigarette smoking

    Percentage of participants self-reporting no smoking over the previous 30 days

    Time frame: At 6 months post-randomization

Secondary outcomes

  1. Biochemically-confirmed 30-day PPA from cigarette smoking

    Percentage of participants reporting no smoking over the previous 30 days, confirmed via carbon monoxide testing

    Time frame: At 6 months post-randomization

  2. Self-reported 7-day PPA from cigarette smoking

    Percentage of participants reporting no cigarette smoking over the prior 7 days

    Time frame: At 8 weeks post-randomization

  3. Self-reported 7-day PPA from cigarette smoking

    Percentage of participants reporting no cigarette smoking over the prior 7 days

    Time frame: At 6 months post-randomization

  4. Self-reported 7-day PPA from use of all nicotine/tobacco products except Food and Drug Administration (FDA)-approved medications

    Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)

    Time frame: At 8 weeks post-randomization

  5. Self-reported 7-day PPA from use of all nicotine/tobacco products except FDA-approved medications

    Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)

    Time frame: At 6 months post-randomization

  6. Self-reported 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications

    Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)

    Time frame: At 8 weeks post-randomization

  7. Self-reported 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications

    Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)

    Time frame: At 6 months post-randomization

  8. Biochemically confirmed 7-day PPA from use of all nicotine/tobacco products except FDA-approved medications

    Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum), confirmed via carbon monoxide and cotinine testing

    Time frame: At 6 months post-randomization

  9. Biochemically confirmed 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications

    Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum), confirmed via carbon monoxide and cotinine testing

    Time frame: At 6 months post-randomization

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The study researchers for this study plan to preserve and share the following: Survey Data: De-identified individual and aggregate survey data (including raw and recoded data) necessary to replicate main outcomes will be shared. The de-identification process will remove direct and indirect respondent identifiers prior to sharing. App utilization data: Individual level, de-identified aggregate data necessary to replicate main outcomes (e.g., summary number of log-ins, pages viewed, or other app events) will be shared. The de-identification process will remove direct and indirect respondent identifiers. Documentation made publicly available to the research community will include PDFs of various study materials. At this time, the study researchers plan to share scientific data and meta-data in NCI's Cancer Data Service (CDS): https://dataservice.datacommons.cancer.gov/#/home.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Final data submission and release of data used in publications will occur at the time of publication. Other shared data will be made available at or before the end of the project period. The study researchers will follow the data retention plan of the final selected repository, but at a minimum, researchers intend to ensure that data is available for a period of not less than 5 years after the end of this trial.

Access criteria: All data sharing will be done in compliance with NIH data sharing policies, applicable laws and regulations, and in accordance with guidance from journal publishers. CDS allows open and controlled access to data to ensure access is provided to qualified researchers, data access is tracked, and users understand how to cite and credit use of the data. Data will only be shared for non-profit, non-commercial and non-proprietary purposes to qualified researchers or as allowed by CDS. Based on the nature of the data, which is not sensitive, the study researchers anticipate making it publicly available (as opposed to controlled access) but will follow final recommendations from the IRB as to whether access should be controlled.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 30 months is above that.

Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Jan 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartEst.
Jan 1, 2027was Nov 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2026→Jan 1, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Nov 1, 2026→Jan 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07493252
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Jaimee Heffner, PhD
Contact
jheffner@fredhutch.org
206-667-7314
Jaimee Heffner, PhD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion